TCTMD: MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

September 29, 2019

Earlier results from the COAPT trial have established that use of a MitraClip (Abbott) on top of guideline-directed medical therapy (GDMT) cuts mortality and heart failure hospitalizations and improves quality of life, but new data show, unsurprisingly, that this comes at a cost.

Suzanne J. Baron, MD, a cardiologist at Saint Luke's Mid America Heart Institute talks to TCTMD about the "acceptable economic value."

Read TCTMD's full article: "MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis"